Association Between PPIs and Hepatocellular Carcinoma Association Between PPIs and Hepatocellular Carcinoma
Might long-term use of proton pump inhibitors increase the risk of hepatocellular carcinoma?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Lenvatinib for Liver Cancer Approved in Europe Lenvatinib for Liver Cancer Approved in Europe
The European Commission granted marketing authorization to lenvatinib as first-line treatment in advanced or unresectable hepatocellular carcinoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 23, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Recurrence of HCC Following Direct-acting Antiviral Therapy Recurrence of HCC Following Direct-acting Antiviral Therapy
Might direct-acting antivirals increase risk and aggressiveness of hepatocellular carcinoma recurrence? This review aimed to characterize HCC recurrence patterns after DAA therapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Diagnostic Value of Serum SMP30, Anti-SMP30 Antibody in HCC Diagnostic Value of Serum SMP30, Anti-SMP30 Antibody in HCC
This study evaluated the utility of anti-SMP30 antibody as a new serological marker for diagnosis of hepatocellular carcinoma.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

FDA Approves Lenvatinib (Lenvima) for Liver Cancer FDA Approves Lenvatinib (Lenvima) for Liver Cancer
The oral therapy lenvatinib joins sorafenib as the only drugs approved for first-line treatment of patients with unresectable hepatocellular carcinoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lenvima (lenvatinib) for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Woodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 – Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 16, 2018 Category: Drugs & Pharmacology Source Type: news

Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma
Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 10, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

The Prevention of HBV-Related Hepatocellular Carcinoma The Prevention of HBV-Related Hepatocellular Carcinoma
This article discusses risk stratification of HBV-related hepatocellular carcinoma and summarizes three levels of preventive strategies.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Medical News Today: New drug may improve liver cancer therapy
Hepatocellular carcinoma (liver cancer) is fast growing, has poor survival rates, and has inefficient current treatments. Can they be improved? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 6, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Scientists develop novel drug that could potentially treat liver cancer more effectively
(National University of Singapore) A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer. This landmark discovery opens door for more effective treatment of liver cancer with less side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

America ’s Drinking Habits Are Killing More Young People, Study Suggests
Liver disease deaths are growing more common in the U.S. and disproportionately affecting younger Americans, according to a recent study. The paper, published in The BMJ just a day after a Centers for Disease Control and Prevention (CDC) report on rising liver cancer death rates, paints a troubling picture of how Americans’ drinking habits may be affecting their health. While the new study couldn’t prove causation, the researchers say drinking is likely to blame for the growing number of adults aged 24 to 35 who are dying from cirrhosis, or scarring of the liver. The researchers used deaths logged in the CDC&r...
Source: TIME: Health - July 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Research Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: World Pharma News)
Source: World Pharma News - July 19, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)
Source: Roche Media News - July 18, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2018 Category: Pharmaceuticals Source Type: news

Cabozantinib Improves Survival in Advanced Hepatocellular Cancer
FRIDAY, July 6, 2018 -- Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to a study published in the July 5 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2018 Category: Pharmaceuticals Source Type: news

Cabozantinib Ups Survival in Advanced Liver Cancer Cabozantinib Ups Survival in Advanced Liver Cancer
Treatment with cabozantinib improved both overall and progression-free survival in previously treated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New combined treatment shows promise in hepatocellular carcinoma
(IDIBELL-Bellvitge Biomedical Research Institute) New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2018 Category: Cancer & Oncology Source Type: news

Ramucirumab Improves Survival in Poor-Prognosis HCC Ramucirumab Improves Survival in Poor-Prognosis HCC
Patients with hepatocellular carcinoma who have high levels of a protein linked to a poor prognosis derive a significant survival benefit with ramucirumab, the results of a pooled analysis reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chinese Herb Prolongs Recurrence-free Survival After Curative Resection of HCC Chinese Herb Prolongs Recurrence-free Survival After Curative Resection of HCC
An aqueous extract of Poria robiniophila called Huaier granule improves recurrence-free survival (RFS) and overall survival after radical surgical resection of hepatocellular carcinoma (HCC), researchers from China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Combines Blueprint Medicines' Lead Clinical Programs with CStone Pharmaceutical's Regional Expertise Expands BLU-554 Development Program in Hepatocellular Carcinoma with Plans to Bring Ongoing Monotherapy Trial to China and Initiate Proof-of-Concept Com... Biopharmaceuticals, Oncology, Licensing Blueprint Medicines, CStone Pharmaceuticals, Avapritinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2018 Category: Pharmaceuticals Source Type: news

Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
SINGAPORE, May 28, 2018 -- (Healthcare Sales & Marketing Network) -- Lion TCR Pte Ltd, a clinical stage biotech pioneering T cell therapy against viral- related cancer, announced today they have raised US$ 20 million in its Series A financing round. The m... Biopharmaceuticals, Oncology, Venture Capital Lion TCR, LioCyx, T-cell, Hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2018 Category: Pharmaceuticals Source Type: news

International team discovers a new anti-cancer protein and it could help doctors treat liver cancer better
(Natural News) Liver cancer is on the rise, with the number of cases tripling in the U.S. since the 1980s. Around 31,000 Americans develop the disease in every year, and 24,000 people die from it. Unfortunately, patients with hepatocellular carcinoma generally have a poor overall prognosis because it’s typically diagnosed in the later stages when... (Source: NaturalNews.com)
Source: NaturalNews.com - April 30, 2018 Category: Consumer Health News Source Type: news

NCCN: Screen for Liver Cancer in Patients at Risk NCCN: Screen for Liver Cancer in Patients at Risk
Hepatocellular carcinoma is a'bad actor'with a growing death toll in the United States and Europe; when possible, patients with risk factors should be screened.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

DAA Treatment for Patients With Hepatocellular Carcinoma DAA Treatment for Patients With Hepatocellular Carcinoma
What factors need to be considered when using DAAs for HCV in patients with HCC? Review recent findings surrounding indications, efficacy and outcomes associated with DAA treatment in these patients.Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Vitamin A derivative selectively kills liver cancer stem cells
(RIKEN) Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer. Now, in research published in Proceedings of the National Academy of Sciences, scientists have discovered that the compound targets one class of cancer stem cells, preventing them from giving rise to new tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2018 Category: Cancer & Oncology Source Type: news

Immunotherapy Prolongs Hepatocellular Carcinoma Survival Immunotherapy Prolongs Hepatocellular Carcinoma Survival
The benefits of immunotherapy with cytokine-induced killer cells continue to be seen in a follow-up extension study of patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Selective internal radiation therapy (SIRT) fails to extend survival in the SORAMIC study palliative cohort
(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2018 Category: Cancer & Oncology Source Type: news

US study reports dramatic reduction in likelihood of liver transplantation in patients with hepatoce
(European Association for the Study of the Liver) ILC 2018: Although hepatocellular carcinoma is now the leading indication for liver transplantation in the USA, the probability of patients receiving a transplant has declined significantly in recent years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2018 Category: International Medicine & Public Health Source Type: news

Sensitive new assay detects hepatitis B infection in single liver cells and serum
(Elsevier) Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples. This assay can be used to diagnose HCC at an earlier stage to manage treatment more effectively. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2018 Category: International Medicine & Public Health Source Type: news

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
(European Association for the Study of the Liver) A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: news

IFN-free Chronic HCV Therapy With DAAs and Risk for HCC IFN-free Chronic HCV Therapy With DAAs and Risk for HCC
Does IFN-free therapy with direct-acting antivirals alter the short-term risk for hepatocellular carcinoma in patients with cirrhosis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Resection Bests Chemoembolization in Selected Liver Cancer Patients Resection Bests Chemoembolization in Selected Liver Cancer Patients
Resection offers survival benefits in carefully selected patients with intermediate-to-advanced hepatocellular carcinoma (HCC), researchers in Korea suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Reduced Overall Survival for Alcohol-Related Liver Cancer
WEDNESDAY, March 28, 2018 -- Reduced overall survival (OS) is seen for patients with alcohol-related hepatocellular carcinoma (HCC), according to a study published online March 28 in Cancer. Charlotte E. Costentin, M.D., from the Public Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

Scientists caution that a rare childhood liver cancer can spread to the brain
(Rockefeller University) A new report details three cases of secondary brain tumors in people with fibrolamellar hepatocellular carcinoma. The researchers say imaging tests could improve treatment for patients whose cancer spreads to the brain from the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 19, 2018 Category: International Medicine & Public Health Source Type: news

Poor Adherence to Hepatocellular Carcinoma Surveillance Poor Adherence to Hepatocellular Carcinoma Surveillance
In this study, the current adherence rates to HCC surveillance guidelines are examined.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cancer stem cells, allies of the tumor and enemies of the patient
(University of Extremadura) Research results point to a therapeutic value for the protein (Ahr) because controlling it might repress the pluripotency of the cancer stem cell and reduce the malignity of the tumour. Indeed, different naturally-occurring molecules have been identified that modulate the activity of this protein in specific ways. In addition, the dioxin receptor might also facilitate the development of tools for the prognosis and evolution of the types of cancer in the study, hepatocellular carcinoma and melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 5, 2018 Category: Cancer & Oncology Source Type: news

New Guidelines for HCC: The Big Questions Tackled New Guidelines for HCC: The Big Questions Tackled
Dr David Johnson provides clinicians with an overview of the new guidelines from the American Association for the Study of Liver Diseases (AASLD) on hepatocellular carcinoma.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2018 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Cabozantinib May Be'New Treatment Option' for Liver Cancer Cabozantinib May Be'New Treatment Option' for Liver Cancer
Cabozantinib improved overall survival and progression-free survival in pretreated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Promising Results for Pembrolizumab in Advanced HCC Promising Results for Pembrolizumab in Advanced HCC
Another immunotherapy has shown efficacy and safety in pretreated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sorafenib Plus TACE Improves Outcomes in HCC Sorafenib Plus TACE Improves Outcomes in HCC
Adding sorafenib to transcatheter arterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (HCC) significantly improved several outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium WOODCLIFF LAKE, N.J., Jan. 19, 2018 -- (Healthcare Sales & Marketing ... Biopharmaceuticals, Oncology Eisai, REFLECT study, lenvatinib, Lenvima, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

EASL and AASLD Recommendations for the Diagnosis of HCC EASL and AASLD Recommendations for the Diagnosis of HCC
This study evaluated the diagnostic performance of CT, MRI and contrast-enhanced ultrasound, alone and in combination.Liver International (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 15, 2017 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news

Bayer receives approval in China for Stivarga ® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)
Approval based on data from the Phase III RESORCE study where Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - December 13, 2017 Category: Pharmaceuticals Source Type: news

13.12.17: Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancerApproval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 12, 2017 Category: Pharmaceuticals Source Type: news

HCC in Chronic HBV vs Chronic HCV After Virologic Response HCC in Chronic HBV vs Chronic HCV After Virologic Response
Does the achievement of virologic response modify the risk of hepatocellular carcinoma differently in patients with chronic hepatitis B as compared to those with chronic hepatitis C?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Elevated Liver Cancer, Death Rates With Chronic HBV Elevated Liver Cancer, Death Rates With Chronic HBV
Patients with immune-tolerant-phase chronic hepatitis B virus (HBV) infection, who are usually not considered for treatment, face an increased risk of hepatocellular carcinoma (HCC) and death, compared with treated immune-active-phase patients, researchers from Korea report.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 22, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

NAFLD Linked to Increased Cancer Incidence Rate
NAFLD strongly tied to development of hepatocellular carcinoma, CRC in males, breast cancer in females (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 20, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Radiology, Journal, Source Type: news

Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer
Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres does not prolong survival compared to sorafenib in patients with advanced hepatocellular carcinoma not eligible for curative treatment, according to French researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 14, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news